Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM6603 in Advanced Solid Tumors
NCT06046066Phase 1Terminated
- Sponsor
- Nucmito Pharmaceuticals Co., Ltd.
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NM6603 in solid tumor, sponsored by Nucmito Pharmaceuticals Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 28 days and Recommended Phase II Dose at 28 days. Started Aug 2023; status: terminated.
02
Drugs
NM6603
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06046066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06046066.